European Update: Spectrum Cannabis enters UK & Poland


2019-01-22 13:49:00 BioSpace


High-quality medical cannabis available today in Polish pharmacies; UK presence positions Spectrum to lead in a key emerging market. SMITHS FALLS, CANADA, OXFORD, UK, TORUŃ, POLAND, Jan. 21, 2019 /PRNewswire/ - Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) ("Canopy Growth" or the "Company") is pleased to update key European progress in the UK and Poland where its medically-focused business Spectrum Cannabis continues to build a sophisticated, pan-European cannabis production and distribution network serving the needs of physicians and their patients throughout the continent. United Kingdom In the United Kingdom the Company has formed Spectrum Biomedical UK, a new company focused on providing access to cannabis-based medicinal products to UK patients with severe unmet clinical need. Spectrum Biomedical UK was formed as a joint venture between Canada's Canopy Growth and Oxford-based research-company Beckley Canopy Therapeutics to address a groundswell of patient need for high quality, standardised cannabis-based medicinal products in the UK. Under the British government's new classification, which took effect November 1, specialist doctors in the UK can prescribe cannabis-based medicines to patients managing a wide range of symptoms - from chronic pain, chemotherapy-induced nausea and vomiting, to muscle spasticity for those with multiple sclerosis.  Following the launch, Spectrum Biomedical UK now has the opportunity to introduce Spectrum Cannabis medicinal cannabis products to UK patient groups and doctors. Spectrum UK will also engage in physician education to ensure doctors are exposed to the deep breadth of research showing the therapeutic benefits of cannabis. The combination of these actions will help build capacity within the UK's healthcare sector, providing patients reliable access to Spectrum Cannabis products and information physicians can use to support them in their practice.  "There is significant real-world and clinical evidence supporting the safety and effectiveness of cannabis-based medicinal products. However, due to the current regulations and lack of education about medicinal cannabis among clinicians in the UK, there remain considerable obstacles to patient access. Spectrum UK has the expertise and ambition to simplify the UK medicinal cannabis landscape and ensure access to cannabis-based medicinal products for patients with great clinical unmet need," said Dr. Mark Ware, Chief Medical Officer, Canopy Growth. Poland In addition to expanding its medicinal cannabis operations in the UK, Canopy Growth's Toruń-based team, Spectrum Cannabis Polska, successfully completed its first import of medical cannabis after completing a rigorous regulatory approval process to have the product assessed and approved for sale.  In last week's import, Spectrum Cannabis Polska received its high-THC whole flower product, Red No. 2. "This shipment is an important first step in a new European market towards building our pan-European operations," says Dr. Pierre Debs, Managing Director, Canopy Growth Europe. "We continue to follow our overall plan of self-sufficiency in Europe to be able to best provide individuals with high-quality medical cannabis." Spectrum Cannabis Polska is a new entity and the fifth of its kind for the Company in European markets. According to the Polish Pharmaceutical Chamber, which represents about 15,000 pharmacies in Poland, it is estimated that up to 300,000 patients could qualify for medical cannabis treatment. The Company is committed to transforming healthcare in Europe by providing better access to medical cannabis treatments that have the potential to improve the lives of millions of patients. Spectrum Cannabis: Medical Cannabis. Simplified. About Spectrum Cannabis Spectrum Cannabis, a wholly-owned subsidiary of Canopy Growth, is dedicated to simplifying medical cannabis for patients and healthcare practitioners. Spectrum Cannabis is an international medical business which interfaces with healthcare professionals and patients around the world. Founded in Canada, Spectrum Cannabis operates in Australia, South America, Africa and across Europe. Spectrum Cannabis products are available in a wide range of potencies and formats designed to simplify the dialogue around strength and dosage by applying a colour-coded Spectrum to categorize medical cannabis according to THC and CBD levels. Its product lineup includes whole flower cannabis, oils and new innovations such as Softgels. Through product simplification, easy dosing formats, and ongoing education of healthcare professionals, Spectrum is committed to improving the lives of medical cannabis patients around the globe. About Canopy Growth Corporation Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. Canopy Growth offers medically approved vaporizers through the Company's subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. The Company has operations in over a dozen countries across five continents. The Company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding of cannabis, and through its wholly owned subsidiary, Canopy Health Innovations ("Canopy Health"), has devoted millions of dollars toward cutting edge, commercializable research and IP development. Canopy Growth works with the Beckley Foundation and has launched Beckley Canopy Therapeutics to research and develop clinically validated cannabis-based medicines, with a strong focus on intellectual property protection. Canopy Growth acquired assets of leading hemp research company, ebbu, Inc. ("ebbu"). Intellectual Property ("IP") and R&D advancements achieved by ebbu's team apply directly to Canopy Growth's hemp and THC-rich cannabis genetic breeding program and its cannabis-infused beverage capabilities. Through partly owned subsidiary Canopy Rivers Corporation, the Company is providing resources and investment to new market entrants and building a portfolio of stable investments in the sector. From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, Battelle, the world's largest nonprofit research and development organization, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates ten licensed cannabis production sites with over 4.3 million square feet of production capacity, including over 500,000 square feet of GMP certified production space. The Company operates Tweed retail stores in Newfoundland and Manitoba and has entered into supply agreements with every Canadian province and territory. For more information visit Notice Regarding Forward Looking Statements This news release contains "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include statements with respect to the Company's international operations in Poland and the UK. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including the Company's ability to satisfy provincial sales contracts or provinces purchasing all cannabis allocated to them, and such risks contained in the Company's annual information form dated June 27, 2018 and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws. View original content to download multimedia: SOURCE Canopy Growth Corporation     Company Codes: NYSE:CGC, Toronto:WEED  
高质量的医用大麻今天在波兰药店;英国的存在使 Spectrum 在一个关键的新兴市场中处于领先地位。 SMITHS FALLS , CANADA , OXFORD , UK , TOROU323, PO兰德,2019年1月21日/ PRNewswire /- Canopy Growth Corporation ( TSX : WEED )( NYSE : CGC )(" Canopy Growth "或"公司")高兴地更新欧洲在英国和波兰的主要进展,在那里,其以医疗为重点的业务 Spectrum Cannabis 继续构建复杂的泛欧洲大麻生产和销售网络,满足欧洲大陆各地医生及其病人的需要。 联合王国 在英国,本公司已成立 Spectrum Biomedical UK ,一家新的公司,专注于向严重未满足临床需求的英国患者提供基于大麻的医药产品。 Spectrum Biomedical UK 是加拿大 Canopy Growth 与总部位于牛津的研究公司 Beckley Canopy Therapeutics 成立的合资企业,旨在解决英国患者对高质量、标准化的大麻药物产品的大量需求。根据英国政府11月1日生效的新分类,英国的专科医生可以给那些有多种症状的患者开出大麻类药物——从慢性疼痛、化疗引起的恶心和呕吐,到多发性硬化症患者的肌肉痉挛。 推出之后, Spectrum Biomedical UK 现在有机会向英国患者团体和医生介绍 Spectrum Cannabis 药用大麻产品。Spectrum UK 还将参与医生教育,以确保医生接触到显示大麻治疗益处的深入研究。这些行动的结合将有助于在英国医疗保健部门建立能力,为患者提供可靠的光谱大麻产品,信息医生可以用来支持他们的实践。 “有重要的现实和临床证据支持基于大麻的医药产品的安全性和有效性。然而,由于目前英国临床医生对医用大麻的监管和教育不足,患者的准入仍然存在相当大的障碍。Spectrum UK 具有简化英国药用大麻景观的专业知识和雄心,并确保为临床上未满足需求的患者提供基于大麻的医药产品,” Canopy Growth 首席医疗官 Mark Ware 博士说。 波兰 除了扩大在英国的药用大麻业务外, Canopy Growth 的 Torun 团队 Spectrum Cannabis Polska 在完成严格的监管审批程序后,成功完成了首次进口医用大麻产品的评估和批准销售。 在上周的进口, Spectrum Cannabis Polska 收到其高 THC 全花产品,红色2号。Canopy Growth Europe 董事总经理 Pierre Debs 博士说:“这批货是欧洲新市场建立泛欧洲业务的重要第一步。”“我们继续遵循我们在欧洲自给自足的总体计划,以便能够最好地为个人提供高质量的医用大麻。” Spectrum Cannabis Polska 是该公司在欧洲市场的第五个新实体。据波兰医药商会估计,多达30万名患者有资格获得医用大麻治疗。该公司致力于通过提供更好的医疗大麻治疗途径来改变欧洲的医疗保健状况,这有可能改善数百万患者的生活。 光谱大麻:医用大麻。简化了。 关于光谱大麻 Spectrum Cannabis 是 Canopy Growth 的全资子公司,致力于为患者和医疗从业者简化医用大麻。Spectrum Cannabis 是一家国际医疗业务,与世界各地的医疗保健专业人员和患者进行沟通。成立于加拿大的 Spectrum Cannabis 在澳大利亚、南美、非洲和整个欧洲开展业务。光谱大麻产品有广泛的效力和格式,旨在简化围绕强度和剂量的对话,应用彩色编码的光谱分类医疗大麻根据 THC 和 CBD 水平。其产品系列包括整株花大麻、油类和软糖等新发明.通过产品的简化、简单的配药方式以及对医疗保健专业人员的持续教育, Spectrum 致力于改善全球医用大麻患者的生活。 关于 Canopy Growth Corporation Canopy Growth 是一家全球领先的多元化大麻和大麻公司,以干、油和软胶囊形式提供不同的品牌和疗效显著的大麻品种。 Canopy Growth 通过公司的子公司 Storz & Bickel GMbH & Co . KG 提供医学认可的蒸发器。从产品和工艺创新到市场执行, Canopy Growth 是由对领导的热情和致力于建立一个世界级的大麻公司一次产品,地点和国家。该公司在五大洲的十几个国家开展业务。 本公司致力于教育医护人员、进行稳健的临床研究及加深公众对大麻的认识,并透过其全资附属公司 Canopy Health Innovations (「 Canopy Health 」)投入数百万美元用于前沿、商业化研究及知识产权开发。Canopy Growth 与 Beckley 基金会合作,推出了 Beckley Canopy Therapeutics ,用于研究和开发基于临床地验证的大麻药物,并大力注重知识产权保护。Canopy Growth 收购了领先的大麻研究公司 ebbu , Inc .(" ebbu ")的资产。ebbu 团队取得的知识产权( IP )和研发进展直接应用于 Canopy Growth 的大麻和富含 THC 的大麻基因育种计划及其大麻输液饮料能力。通过部分拥有的子公司 Canopy Rivers Corporation ,该公司为新进入市场的企业提供资源和投资,并在该行业建立稳定的投资组合。 从多伦多证券交易所( Toronto Stock Exchange )和纽约证券交易所( New York Stock Exchange )历史上的公开上市,到我们持续的国际扩张,我们对通过领导力提升股东价值感到自豪,这是我们在 Canopy Growth 所做的一切。Canopy Growth 与大麻图标 Snoop Dogg 、育种传奇人物 DNA 遗传学和绿屋种子、全球最大的非盈利研发组织 Battelle 以及《财富》500强酒精领袖星座品牌等知名行业建立了合作关系。Canopy Growth 经营着10个有执照的大麻生产场所,拥有超过430万平方英尺的生产能力,包括超过50万平方英尺的 GMP 认证生产场所。公司在纽芬兰和马尼托巴省经营 Tweed 零售店,并与加拿大各省和地区签订供货协议。有关详细信息,请访问 有关前瞻性陈述的公告 本新闻发布会包含1995年美国私人证券诉讼改革法案意义内的“前瞻性陈述”和适用加拿大证券立法意义内的“前瞻性信息”。通常但并非总是,前瞻性陈述和信息可以通过使用诸如“计划”、“预期”或“不预期”、“预期”、“估计”、“意图”、“预期”或“不预期”或“相信”等词和短语或陈述某些行动、事件或结果“可能”、“可能”、“将”的变化来识别。"可能"或"将"采取、发生或实现。前瞻性陈述或信息涉及已知和未知的风险、不确定性和其他可能导致 Canopy Growth 或其子公司的实际业绩、业绩或业绩与任何未来业绩产生重大差异的因素;本新闻稿所载前瞻性陈述或信息所表达或暗示的业绩或成就。此类声明的例子包括有关公司在波兰和英国的国际业务的声明。 与前瞻性信息相关的风险、不确定性和其他因素可能导致实际事件、结果、业绩、前景和机会与此类前瞻性信息明示或暗示的情况存在重大差异,包括本公司有能力履行省级销售合同或省份采购分配给他们的所有大麻,以及本公司日期为6月27日的年度信息表中包含的此类风险。2018年向加拿大证券监管机构备案,可在 SEDAR 网站 上查阅本公司的发行人简介。尽管本公司认为编制本新闻稿中的前瞻性信息或前瞻性陈述所使用的假设和因素是合理的,但不应过分依赖该等信息,也不能保证该等事件将在披露的时间框架或任何时候发生。本新闻稿所载的前瞻性资料及前瞻性陈述乃于本新闻发布会刊发日期作出,本公司并无责任公开更新该等前瞻性资料或前瞻性资料以反映新资料。后续事件或其他,除非适用的证券法要求。 查看下载多媒体的原始内容:。html SOURCE Canopy Growth Corporation 公司代码: NYSE : CGC , Toronto : WEED